Clonazolam
Viewing r1 — May 8, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Clonazolam is a synthetic depressant of the triazolobenzodiazepine class. It is the triazolo structural analog of clonazepam, distinguished by exceptional potency. Clonazolam is a positive allosteric modulator of GABA-A receptors, producing its effects by amplifying inhibitory signaling throughout the central nervous system.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
benzodiazepines, Z-drugs (zolpidem, zopiclone, zaleplon), barbiturates +1 morebenzodiazepines, Z-drugs (zolpidem, zopiclone, zaleplon), barbiturates, alcohol show less
Synthesized in 1971 by Hester at the Upjohn Company as part of a triazolobenzodiazepine research series,[2] clonazolam was never developed into a pharmaceutical product. It appeared on illicit online drug markets around 2014,[3] rapidly becoming one of the most potent designer benzodiazepines in circulation. It is now temporarily Schedule I in the United States, Class C in the United Kingdom, and recommended for international scheduling by the WHO.[4]
Subjective effects include sedation, amnesia, muscle relaxation, anxiolysis, and disinhibition. The experience is deceptively mild in self-perception — a pervasive calm and muscular looseness that masks severe cognitive and motor impairment, combining with dense memory blackouts to create a feedback loop favorable to compulsive redosing.[5] Delusions of sobriety, complete anterograde amnesia, and unrecognized motor impairment are characteristic unsought effects.
Clonazolam produces rapid physical dependence, and respiratory depression is the primary lethal mechanism — the first confirmed single-substance fatality involved a 14-year-old who ingested counterfeit alprazolam tablets.[6] Tolerance develops within days of continuous use, driving dose escalation; the short half-life accelerates interdose withdrawal, and cessation carries seizure risk requiring medically supervised taper.[7] No controlled human studies have been conducted; the evidence base consists entirely of forensic case reports, in vitro metabolism studies, and review literature.
History[edit]
Discovery
Clonazolam was first synthesized in 1971 by Jackson B. Hester Jr. at the Upjohn Company, the pharmaceutical firm that later brought alprazolam to market.[2] The synthesis was part of a systematic exploration of triazolobenzodiazepines — compounds formed by fusing a triazole ring to existing 1,4-benzodiazepine scaffolds. Described at the time as the most potent compound in the series tested,[4] clonazolam was never advanced into clinical development and remained confined to patent literature for more than four decades.[1]
Market emergence and public health impact
Clonazolam surfaced on illicit online drug markets around 2014,[3] part of a broader designer benzodiazepine wave that had begun with phenazepam around 2007.[8] Bulk prices as low as five to ten US cents per dose made it readily accessible,[9] and its appearance marked a significant potency escalation within the novel psychoactive substance benzodiazepine market. A critical public health concern is its incorporation into counterfeit pharmaceutical tablets — particularly fake Alprazolam — confirmed by wastewater monitoring[10][11] and by the first confirmed single-substance death, in which a 14-year-old victim believed he was consuming pharmaceutical alprazolam.[6]
Prohibition and scheduling
Regulatory response lagged nearly a decade behind market appearance. Moosmann et al. published the first formal public health warning in 2015,[9] and the WHO recommended international scheduling in 2020.[4] The United States did not temporarily place clonazolam in Schedule I until July 2023,[12] with permanent scheduling proceedings initiated in 2025.[13] Prior to specific scheduling, its legal status under the US Federal Analogue Act was uncertain.[9]
The name follows benzodiazepine pharmaceutical convention: "clona-" derives from its structural parent clonazepam, while "-zolam" signals the triazole ring fusion shared with Alprazolam and triazolam. The compound has no established street names distinct from its chemical name, reflecting circulation primarily through online research chemical markets rather than traditional street-level distribution. Among users, it carries a reputation as one of the most dangerous designer benzodiazepines — a reputation earned largely through its association with blackouts, compulsive redosing, and counterfeit tablet fatalities.
Chemistry[edit]
Structural class
Clonazolam belongs to the triazolobenzodiazepine subclass — a 1,4-benzodiazepine scaffold fused with a 1-methyl-1,2,4-triazole ring at the 1,2-position. This structural modification is shared with pharmaceutical agents including alprazolam and triazolam. Clonazolam can be understood as the triazolo structural analog of clonazepam: it retains clonazepam's 2-chlorophenyl group and 8-nitro group while adding the triazole ring that defines the series.[1]
The triazole fusion generally increases potency and shortens duration of action relative to the parent benzodiazepine. In clonazolam, the combination of an electron-withdrawing nitro group at position 8 and the 2-chlorophenyl ring at position 6 produces exceptionally high GABA-A affinity within the triazolobenzodiazepine class.[4]
IUPAC name: 6-(2-chlorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine.
Molecular properties
| Molecular formula | C₁₇H₁₂ClN₅O₂ |
| Molecular weight | 353.8 g/mol |
The molecule features a seven-membered diazepine ring fused to a benzene ring bearing the nitro substituent, with the triazole ring annulated at the 1,2-position. The 2-chlorophenyl group at position 6 sits perpendicular to the benzodiazepine plane — a conformation critical for binding at the benzodiazepine recognition site. The methyl group on the triazole ring modulates lipophilicity and metabolic stability.
Stereochemistry
Clonazolam does not contain a chirality center. The compound exists as a single constitutional isomer, and no stereoselective pharmacology has been reported.
Physical properties
No peer-reviewed characterization of clonazolam's melting point, solubility, or partition coefficient has been published. In forensic settings, it appears as a white to off-white powder. The triazolobenzodiazepine scaffold is generally considered chemically stable under ambient conditions.citation needed
Pharmacology[edit]
Mechanism of action
Clonazolam binds the benzodiazepine recognition site on GABA-A receptors — the brain's primary inhibitory signaling system. Like all benzodiazepines, it does not activate the receptor directly but amplifies the effect of the neurotransmitter GABA, increasing the frequency with which inhibitory ion channels open. The result is widespread suppression of nervous system activity, producing sedation, anxiety relief, muscle relaxation, and anticonvulsant effects.[1]
No binding affinity or potency values specific to clonazolam have been published in peer-reviewed literature. Computational modeling predicts high biological activity, consistent with optimal placement of functional groups within the benzodiazepine binding pocket.[14]
In practice, clonazolam is more than twice as potent as alprazolam by effective dose.[5][15] The WHO described it as the most potent compound in the triazolobenzodiazepine series, with typical doses of 0.2–0.4 mg — far below most marketed benzodiazepines.[4] Strong sedation and amnesia occur at doses as low as 0.5 mg.[9]
Pharmacokinetics
No formal human pharmacokinetic study has been published. All parameters are estimated from the WHO critical review, forensic case data, and structural analogy to related triazolobenzodiazepines.
Oral onset is estimated at 20–60 minutes.[4] The half-life is approximately 3.6 hours,[4] classifying clonazolam as a short-to-medium-acting benzodiazepine. The discrepancy between this short half-life and the 6–10-hour subjective duration may reflect active metabolite accumulation or prolonged receptor occupancy.
The primary metabolite is 8-aminoclonazolam, produced by reduction of the nitro group. This metabolite predominates over the parent compound in biological samples — in one fatality case, 8-aminoclonazolam was detected at 140 ng/mL while the parent compound was not separately reported.[6] Additional metabolic pathways include hydroxylation, dealkylation, and glucuronidation.[16][17]
Oral bioavailability, volume of distribution, and protein binding have not been characterized. By structural analogy with Alprazolam, clonazolam is expected to distribute readily into brain tissue.inferred Specific CYP enzyme involvement has not been directly demonstrated, though CYP3A4 is the most likely primary metabolizing enzyme based on the metabolism of structurally related compounds.inferred
Neuroscience[edit]
Where it acts
Clonazolam enhances inhibitory signaling across the brain by potentiating GABA-A receptors distributed throughout cortical and subcortical regions. Sedation and sleep induction arise from receptors concentrated in the thalamus and cortex, where enhanced inhibition suppresses arousal pathways. Anxiety relief traces to the amygdala, where dampened activity reduces fear circuit output.
The profound amnesia characteristic of clonazolam — occurring even at doses below the sedation threshold — reflects disruption of memory consolidation in the hippocampus, where GABA-A potentiation interferes with the cellular processes underlying new memory formation. Respiratory depression, the primary lethal risk, involves suppression of brainstem breathing centers — a mechanism that becomes catastrophic when compounded by opioid-mediated respiratory suppression through separate pathways.
Why it matters
The reinforcing properties driving clonazolam dependence operate through an indirect mechanism: the compound silences inhibitory interneurons in the brain's reward circuitry, disinhibiting dopamine-releasing neurons and increasing dopamine release in the nucleus accumbens. Tolerance to euphoria develops faster than the motivational drive to redose, creating a pattern where compulsive use persists after the rewarding effects have diminished.[5]
Chronic exposure triggers compensatory neuroadaptation: GABA-A receptors decrease in number and sensitivity while excitatory glutamate signaling ramps up. Upon abrupt cessation, this rebalancing produces a hyperexcitable state manifesting as anxiety, insomnia, tremor, and at extremes, seizures. The short half-life of clonazolam (~3.6 hours) means this withdrawal state can emerge within hours of the last dose.
Whether clonazolam shows preferential activity at specific GABA-A receptor subtypes is unknown — the pronounced amnesia at sub-sedating doses hints at possible selectivity for hippocampal receptors, but no binding data exist to test this. Whether 8-aminoclonazolam, the primary metabolite, retains significant GABA-A activity could explain the gap between the parent compound's short half-life and the 6–10-hour subjective duration.
Subjective Effects[edit]
At common doses, clonazolam delivers a pervasive sedation and muscular looseness that users consistently underestimate. The compound's defining quality is the gap between how impaired a person feels and how impaired they are — delusions of sobriety mask severe cognitive and motor deficits while dense amnesia erases awareness of doses already taken. Higher doses deepen this disconnect rather than resolving it, progressing toward blackout without subjective warning. Set and setting have limited moderating influence; the pharmacology dominates the experience.
Compared to alprazolam, clonazolam is substantially more potent and more amnestic at equivalent effect levels. Relative to its parent compound clonazepam, it trades the long, gradual onset for rapid, intense effects that resolve more quickly — a pharmacokinetic profile that accelerates both tolerance development and interdose withdrawal.
Effect Grid
At common doses (200–400 µg oral), clonazolam produces pronounced sedation and strong anxiety suppression. Anterograde amnesia becomes prominent — extended periods may pass without memory formation. Delusions of sobriety typically emerge at this level: users consistently underestimate their degree of impairment, believing themselves functional while exhibiting obvious motor and cognitive deficits. Euphoria is reported by some users, alongside marked disinhibition and emotional suppression.
Motor control impairment is significant — ataxia, slurred speech, and impaired coordination are common. Muscle relaxation is strong. Respiratory depression is present but typically subclinical at this dose range in isolation.
This is the dose range most associated with compulsive redosing, as amnesia erases awareness of doses already taken while delusions of sobriety suppress the judgment needed to stop.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Vestibular distortion · Proprioceptive distortion · Visual haze / noise · Visual processing suppression
Body high · Dizziness · Nystagmus (eye wobbles) · Breathing alteration · Insomnia · Laughter fits · Pain suppression · Yawning · Nausea · Salivation · Bodily dissociation
Insomnia · Laughter fits · Pain suppression · Yawning · Nausea · Salivation · Bodily dissociation
Analysis suppression · Cognitive fatigue · Delusions of sobriety · Information processing suppression · Memory fragmentation · Thought deceleration · Confusion · Cognitive euphoria · Creativity suppression · Language suppression · Motivation suppression · Suggestibility enhancement · Thought disorganization · Amnesia · Delirium · Delusions
Memory fragmentation · Thought deceleration · Confusion · Cognitive euphoria · Creativity suppression · Language suppression · Motivation suppression · Suggestibility enhancement · Thought disorganization · Amnesia · Delirium · Delusions
Dysphoria · Emotional lability · Anxiety
Sociability enhancement · Communication suppression · Depersonalization · Derealization · Cognitive disconnection · Identity alteration
Cognitive disconnection · Identity alteration
Timeline
Gradual emergence of anxiolysis and mild sedation. Effects may not be immediately perceived, particularly at lower doses — onset can be subtle enough to prompt premature redosing.
Sedation deepens noticeably and muscle relaxation becomes apparent. Cognitive slowing begins; anterograde amnesia may start at common+ doses.
Maximum sedation, amnesia, and anxiolysis. Motor impairment most pronounced — ataxia and slurred speech. Delusions of sobriety peak here; compulsive redosing risk is highest.
Gradual reduction in sedation intensity. Amnesia may persist beyond subjective awareness of impairment. Residual motor control impairment and drowsiness continue.
Residual sedation, cognitive fog, and possible next-day impairment. Sleep quality may be disrupted. Subtle motor and cognitive deficits may persist beyond subjective awareness.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Moderate
- Withdrawal
- Life-threateningfatal risk
- Tolerance buildup
- rapid
- Tolerance reset
- 10.5 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- benzodiazepines · Z-drugs (zolpidem, zopiclone, zaleplon) · barbiturates
Toxicity
Acute toxicity
No LD₅₀ has been established for clonazolam in any species, and no controlled toxicity studies exist.[4] The primary lethal mechanism is respiratory depression — suppression of the brain's breathing drive sufficient to cause respiratory arrest.
The first confirmed single-substance death involved a 14-year-old male who ingested counterfeit alprazolam tablets. Toxicology identified 8-aminoclonazolam at 140 ng/mL in postmortem blood; death was attributed to cerebral and respiratory depression from acute clonazolam intoxication.[6]
A polysubstance fatality involved clonazolam at 2,080 ng/mL alongside flualprazolam, opioids (thebaine, codeine, morphine), and a synthetic cannabinoid — combined CNS and respiratory depression proved fatal.[18] Population-level data from Australia show increasing novel benzodiazepine involvement in fatal overdoses.[19]
Reversal
Flumazenil, a benzodiazepine antagonist, can reverse clonazolam-induced respiratory depression and sedation.[4] However, flumazenil's short duration (40–80 minutes) may require repeat dosing given clonazolam's longer effect window. In benzodiazepine-dependent individuals, flumazenil carries seizure risk.
Chronic toxicity
No studies have assessed organ damage from repeated clonazolam use. By class inference, chronic benzodiazepine exposure is associated with cognitive impairment (particularly memory), increased fall risk in older adults, and potential developmental harm with prenatal exposure.inferred Whether clonazolam's exceptional potency produces additional organ-specific toxicity is unknown.
Psychological risks
Clonazolam's profound amnestic properties dominate its psychological risk profile. Amnesia occurs at sub-sedating doses, producing periods of memory blackout during which the individual remains ambulatory and superficially functional — a state conducive to dangerous behavior, accidental injury, and unknowing redosing.[9] Delusions of sobriety compound this risk by suppressing the self-awareness that would normally prevent dose escalation.
The compound has been specifically identified as a drug-facilitated sexual assault risk due to its rapid onset, high potency, profound amnesia at sub-sedating concentrations, and limited detectability in standard drug screens.[20]
Driving impairment is well documented. Clonazolam and its primary metabolite have been detected in impaired-driving blood samples across a five-year surveillance period, with observed driving behavior consistent with severe CNS depression including lane deviation, slowed reaction time, and impaired coordination.[21]
Tolerance and dependence
Tolerance to clonazolam's sedative and anxiolytic effects develops within days of continuous use.[5][8] The underlying mechanism is compensatory reduction in GABA-A sensitivity. Cross-tolerance with all other benzodiazepines, Z-drugs (zolpidem, zopiclone), and likely alcohol is expected given the shared receptor target.
Clonazolam carries high dependence liability. Rapid tolerance drives dose escalation; the short half-life produces interdose withdrawal symptoms; and compulsive redosing is fueled by disinhibition, euphoria, and amnesia-mediated loss of dose tracking.[5] Historically low cost and high availability have further reduced barriers to escalating use.[9]
Multiple clinicians have documented the difficulty of managing designer benzodiazepine dependence involving clonazolam.[22][23][24]
Withdrawal from clonazolam is clinically dangerous. The short half-life (~3.6 hours) predicts rapid withdrawal onset — potentially within 6–12 hours of the last dose. Symptoms include rebound effect anxiety, insomnia, tremor, autonomic instability, and seizures, which can be life-threatening.
No clonazolam-specific withdrawal protocol exists. Management follows general benzodiazepine withdrawal practice: substitution with a long-acting benzodiazepine (typically diazepam) followed by gradual dose reduction over weeks to months.[7] The dose equivalence between clonazolam and diazepam has not been established in controlled studies, complicating initial substitution dosing.
Drug interactions
Pharmacodynamic interactions
Combining clonazolam with any CNS depressant produces additive or synergistic respiratory depression.
Opioids represent the most dangerous documented combination. Respiratory depression occurs through complementary mechanisms, and concurrent use carries a mortality hazard ratio of 1.78 compared to opioids alone.[25] Illicitly obtained benzodiazepines frequently contain opioid contaminants, adding an uncontrolled additional risk.[1][26]
Alcohol produces additive CNS depression via overlapping GABAergic mechanisms.
Other benzodiazepines, Z-drugs, and barbiturates produce purely additive effects at the same receptor target.
GHB/GBL and baclofen potentiate CNS depression via a complementary inhibitory pathway (GABA-B).
Pharmacokinetic interactions
By class inference, potent CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) are expected to increase clonazolam blood levels, while CYP3A4 inducers (rifampin, carbamazepine) would reduce them.inferred No clonazolam-specific drug interaction studies have been published.
Contraindications
Absolute contraindications
- Concurrent opioid use: The additive respiratory depression is the best-documented lethal interaction for clonazolam.[18][25]
- Severe breathing difficulties: Pre-existing respiratory compromise eliminates the safety margin for benzodiazepine-induced respiratory depression.
- Severe liver disease: Reduced metabolic capacity is expected to increase clonazolam exposure.inferred
Relative contraindications
- Pregnancy: Benzodiazepines cross the placenta; class-level evidence associates prenatal exposure with birth defects and neonatal withdrawal.inferred
- Older adults: Increased sensitivity to CNS depressant effects; elevated fall and fracture risk.
- Adolescents: The first confirmed single-substance fatality involved a 14-year-old.[6]
- History of substance use disorder: High reinforcement potential and compulsive redosing risk.
- Myasthenia gravis: muscle relaxation effects can worsen neuromuscular weakness.inferred
Detection limitations
Standard benzodiazepine urine tests show variable cross-reactivity with clonazolam.[27] Definitive identification requires specialized laboratory analysis (LC-MS/MS), which is unavailable in many clinical settings. This creates a risk of misidentification or missed detection in emergency presentations.
Harm Reduction[edit]
Forms & Identification
Clonazolam's microgram-level potency makes visual identification of dose unreliable across all forms. Pressed tablets and blotters may contain anywhere from sub-threshold to dangerously high amounts, and batch-to-batch variation is common in unregulated production. Standard benzodiazepine immunoassay panels detect clonazolam inconsistently — a negative result does not rule out its presence.
The most consequential identification challenge is distinguishing clonazolam-containing counterfeit tablets from genuine pharmaceuticals. Counterfeit alprazolam tablets containing clonazolam are visually indistinguishable from the real product. Any benzodiazepine tablet obtained outside a licensed pharmacy should be treated as unverified.
Guidelines
- Test any substance of unknown provenance before use. Reagent testing cannot confirm clonazolam specifically but can rule out some substitutions.
- Use volumetric dosing when working with powder or concentrated solutions. Eyeballing microgram-active substances is not possible with any accuracy.
- Pre-measure a single dose and physically separate or secure remaining material before onset. Amnesia and delusions of sobriety make in-session dose decisions unreliable.
- Inform a trusted person of the substance, dose, and timing.
- Avoid redosing. If the effects feel insufficient, wait the full onset window (up to 60 minutes) before concluding the dose was sub-threshold.
- Never combine with opioids, alcohol, or other sedatives.
Set & Setting
Clonazolam's amnestic and disinhibiting properties make environmental control unusually important. Use in unfamiliar or high-risk settings (near traffic, bodies of water, heights) carries elevated danger because the user may lose awareness of surroundings while remaining ambulatory. A sober companion who understands the compound's effects — particularly the likelihood that the user will insist they are fine when they are not — significantly reduces the risk of accidental injury and compulsive redosing.
Aftercare & integration. The dense amnesia produced by clonazolam often leaves users with incomplete or absent memory of periods lasting hours. Reviewing texts, call logs, and surroundings after the experience can help reconstruct events and identify any actions taken during blackout that require follow-up.
Physical recovery is typically straightforward — residual grogginess and mild cognitive fog may persist for 12–24 hours. Adequate sleep, hydration, and nutrition support recovery. If the experience involved a blackout or unintended redosing, reassess the circumstances that led to use and the adequacy of dose control measures.
Recovery & Support
Clonazolam dependence develops rapidly and withdrawal is medically dangerous. Do not attempt to stop abruptly after regular use — seizures from unsupervised benzodiazepine withdrawal can be fatal. Medical supervision is strongly recommended for any taper.
A physician experienced in benzodiazepine withdrawal management can establish a substitution and taper protocol, typically using a long-acting benzodiazepine such as diazepam. The Ashton Manual is a widely referenced guide for benzodiazepine tapering. Support communities such as BenzoBuddies and r/benzorecovery provide peer support specific to benzodiazepine dependence.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Breathing that is slow, shallow, or irregular; blue or grey discoloration of lips or fingertips; inability to be roused by voice or firm stimulation; seizure activity (rhythmic jerking, loss of consciousness). Any of these signs require immediate action.
Immediate steps:
- 1. Call emergency services.
- 2. Place the person on their side in the recovery position to protect the airway.
- 3. Monitor breathing continuously. If breathing stops, begin rescue breathing if trained.
- 4. Do not leave the person alone.
- 5. Do not induce vomiting.
- 6. Do not attempt to "walk them off" or administer stimulants.
What to tell the dispatcher: The substance name (clonazolam), approximate amount and time of ingestion, current symptoms (especially breathing rate and responsiveness), and whether any other substances were co-ingested. Good Samaritan laws in many jurisdictions protect callers from prosecution for drug-related offenses when seeking emergency help.
Reversal agent: Flumazenil can reverse benzodiazepine-induced respiratory depression and is available to emergency medical personnel. It has a shorter duration than clonazolam's effects and may require repeat dosing. In dependent individuals, flumazenil can trigger seizures — inform responders if the person uses benzodiazepines regularly.
Legal Status[edit]
Clonazolam occupies an increasingly restricted legal position globally. The WHO recommended international scheduling in 2020,[4] and major jurisdictions have enacted or initiated domestic scheduling over the 2017–2025 period. Prior to specific scheduling, its legal status was uncertain in many countries — it was unclear whether designer benzodiazepines fell under existing structural analog legislation.[9]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (temporary; permanent proceedings initiated) | Temporarily placed July 26, 2023;[12] extended to July 26, 2026; permanent scheduling initiated July 2025[13] |
| United Kingdom | Class C (Misuse of Drugs Act 1971) | Classified under May 2017 amendmentcitation needed |
| Australia | Schedule 9 (Prohibited Substance) | Federal scheduling under the Therapeutic Goods Actcitation needed |
| International | WHO recommended Schedule IV | 43rd ECDD (2020) recommended placement in Schedule IV of the Convention on Psychotropic Substances 1971[4] |
| Canada | Not independently confirmed | No specific scheduling data identified in available sources |
| European Union | Varies by member state | Flagged by the EU Early Warning System; individual member states may have enacted national schedulingcitation needed |
The US scheduling trajectory illustrates the regulatory lag characteristic of designer drugs: clonazolam appeared on illicit markets in 2014, was flagged as a public health concern in 2015,[9] and was not federally scheduled until 2023 — a nine-year gap during which its legal status under the Federal Analogue Act remained uncertain.
references
- [1]
- [2]
- [3] ^abSyrjanen R, Greene SL, Castle JW, Di Rago M, Hodgson SE, Abouchedid R, Graudins A, Schumann JL (2023) Non-fatal intoxications involving the novel benzodiazepine clonazolam: case series from the Emerging Drugs Network of Australia - Victoria project. — Clinical Toxicology doi:10.1080/15563650.2023.2183105
- [4]
- [5]
- [6]